Immune/JJ
functions/NNS
,/,
clinical/JJ
parameters/NNS
and/CC
hormone/NN
receptor/NN
status/NN
in/IN
breast/NN
cancer/NN
patients/NNS
./.

We/PRP
have/VBP
carried/VBN
out/RP
a/DT
detailed/JJ
analysis/NN
of/IN
the/DT
cellular/JJ
immune/JJ
functions/NNS
of/IN
breast/NN
cancer/NN
patients/NNS
in/IN
comparison/NN
with/IN
healthy/JJ
controls/NNS
./.
=====
A/DT
possible/JJ
correlation/NN
between/IN
immune/JJ
and/CC
clinical/JJ
parameters/NNS
was/VBD
analysed/VBN
in/IN
50/CD
breast/NN
cancer/NN
patients/NNS
./.
=====
Immune/JJ
parameters/NNS
,/,
natural/JJ
killer/NN
cell/NN
and/CC
T/NN
lymphocyte/NN
functions/NNS
and/CC
the/DT
numbers/NNS
of/IN
circulating/VBG
T/NN
lymphocytes/NNS
were/VBD
analysed/VBN
against/IN
the/DT
clinical/JJ
parameters/NNS
comprising/VBG
the/DT
tumour/NN
burden/NN
,/,
the/DT
stage/NN
of/IN
the/DT
disease/NN
and/CC
the/DT
expression/NN
of/IN
hormone/NN
receptors/NNS
on/IN
the/DT
tumour/NN
./.
=====
In/IN
order/NN
to/TO
analyse/VB
the/DT
immune/JJ
function/NN
data/NNS
effectively/RB
,/,
low/JJ
responders/NNS
were/VBD
identified/VBN
with/IN
stringent/JJ
cut-off/JJ
values/NNS
./.
=====
Considerably/RB
higher/JJR
proportions/NNS
of/IN
low/JJ
responders/NNS
were/VBD
found/VBN
among/IN
the/DT
patient/NN
population/NN
./.
=====
Elevated/JJ
numbers/NNS
of/IN
circulating/VBG
T/NN
lymphocytes/NNS
and/CC
CD3-directed/JJ
cytolysis/NN
correlated/VBD
with/IN
the/DT
expression/NN
of/IN
oestrogen/NN
receptors/NNS
independently/RB
of/IN
the/DT
clinical/histological/JJ
parameters/NNS
./.